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Summary The in vivo characteristics of four analogues of benzoporphyrin derivative (BPD) have been
investigated. Biodistribution data obtained in DBA/2J mice with BPD-MA (monoacid ring A analogue) which
had been tritiated or internally labelled with '4C showed that both labelled materials acted in an essentially
identical manner during the period of study. Biodistribution and clearance studies showed that relative
distribution in a variety of mouse tissues was simlar for all BPD analogues. MI tumour cells (rhabdomyosar-
coma in DBA/2J mice) taken from tumours excised from animals treated 3 h earlier with BPD, and tested in
vitro for photosensitivity provided evidence that significant levels of photosensitiser detected in tumour was
both active and associated with tumour cells. The monoacid forms of BPD were found to be much more
photodynamically active in this test than were the diacid analogues. The ability of the analogues to ablate
tumours in mice by photodynamic therapy was also tested. Again, BPD-MA and BPD-MB proved to be
measurably better than the diacid analogues. These findings are discussed in reference to structural and
physical differences between the analogues.
Photodynamic therapy (PDT) is based on the observation
that many photosensitisers accumulate somewhat selectively
in tumour tissue where they can be activated by light at a
desired wavelength. Most of the clinical work on PDT has
been carried out with hematoporphyrin derivative (HPD) or
Photofrin® (formerly Photofrin II), both preparations which
contain a large number of porphyrin derivatives (Dougherty,
1987; Kessel et al., 1987). The composite nature of these
preparations, which are known to be effective for PDT, have
made definitive research on precisely what characteristics of a
photosensitiser contribute most to optimal selectivity in
tumour uptake and cytotoxicity very difficult.
Results obtained with chemically defined photosensitisers
such as various phthalocyanines, purpurins and chlorins,
while very useful in expanding the knowledge of photosen-
sitiser use in experimental PDT models, have yet to answer
the difficult questions regarding which characteristics of a
particular molecule are those which enable cell killing and
selective delivery to tumours (Brasseur et al., 1988; Kreimer-
Birnbaum, 1989; Morgan et al., 1987a,b). Undoubtedly, the
knowledge of these characteristics could help in selecting
and/or designing photosensitisers for PDT. It appears likely,
however, that no photosensitiser will have all of the desirable
properties since no doubt, efficacious PDT is dependent on a
large number of variables.
We have been working with a chlorin-like photosensitiser,
benzoporphyrin derivative (BPD), which is composed of four
structural analogues following synthesis. All four analogues
have an identical reduced tetrapyrrol porphyrin ring. They
differ in two regards; the position of a cyclohexadiene ring
which is fused at either ring A or B of the porphyrin, or in
the presence of two acidic groups, or one acid and one ester
group located at positions C and D of the porphyrins. In
vitro characteristics of these analogues have been reported
earlier (Richter et al., 1990a). Monoacid analogues were
found to be more efficient photosensitisers than the diacids.
Of the two monoacids, monoacid ring B (BPD-MB) was
found to be slightly more soluble than the ring A analogue
(BPD-MA) and preliminary in vivo work indicated that this
could be a problem in obtaining reliable data because of the
possible presence of aggregates in formulated materials.
Therefore our studies on in vivo photosensitisation with BPD
have focused largely on BPD-MA. The results are reported in
this paper. We also report the results of limited studies
carried out with other BPD analogues, undertaken in order
to identify special characteristics which make a molecule of a
photosensitiser efficient in in vivo PDT.
Materials and methods
Synthesis ofBPD analogues
BPD was synthesised as described earlier (Richter et al.,
1987). The length ofhydrolysis of the dimethylester ofA-ring
or B-ring isomers with 25% hydrochloric acid dictates the
final ratio between mono and diacids formed, longer hydro-
lysis leading to more complete conversion to the diacid form.
The separation of the diacids from the monoacid analogues
was carried out using column chromatography on silica gel
as described earlier (Richter et al., 1990b). The following
analogues were obtained: BPD-monoacid, ring A (BPD-MA),
and ring B (BPD-MB), and BPD diacid, ring A (BPD-DA)
and ring B (BPD-DB).
All four BPD analogues were maintained in dimethyl sulf-
oxide (DMSO) at a concentration of 8 mg ml-'. Immediately
before injection into the animals they were diluted in phos-
phate buffered saline (PBS). The injected solution contained
no more than 10% DMSO.
Tritiated BPD analogues
Batches of BPD-MA, -MB and -DA were tritiated by NEN
(Boston, Mass.) according to the procedure described earlier
(Richter et al., 1990b). Two batches of BPD-MA were label-
led and the specific activities were 5.9 mCi mg-' (1st batch)
and 5.46 mCi mg-' (2nd batch). Specific activities of BPD-
MB and BPD-DA were 9.2 mCi mg-' and 6.57 mCi mg-',
respectively. The labelled compounds were tested for purity
and photosensitising activity before use as previously des-
cribed (Richter et al., 1990b). Tritiated compounds were not
as stable as unlabelled compounds. During these studies,
several aliquots were purified by column chromatography
and rechecked for purity and photosensitising activity before
use. In this work, purity and photosensitising activity were
routinely assessed prior to experimental use of labelled
materials.
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"'C carbon ("1C) labelled BPD-MA and BPD-DA
The radioactive compounds were synthesised by one of us
(E.D.S.) by means of the routine method for synthesis of
BPD (as described previously, Ritcher et al., 1990b), except
that one of the starting compounds was replaced with a
radioactive equivalent. Namely, protoporphyrin IX, purified
in our laboratory, was reacted with dimethylacetylenedicarb-
oxylate (2,3-'4C) (specific activity 44.0 mCi mmole-'; New
England Nuclear, Boston, Mass.). The final compounds, '4C-
BPD-MA and '4C-BPD-DA, had "'C incorporated in the
cyclohexadiene ring and were pure as determined by TLC.
The specific activity was 60.8 and 60.1 jsCi mg-' for mono-
acid and diacid, respectively. The radioactivity corresponded
to the cytotoxic activity as tested in the routine assay in vitro.
The labelled compounds were stored at - 70°C in DMSO,
and diluted before experiments according to the same proce-
dure as cold analogues.
Animals and tumours
DBA/2 mice (8 to 12 weeks old) were used throughout the
study and were supplied either by Jackson Laboratories (Bar
Harbor, Maine) or Charles River Laboratories (St Constant,
Quebec). For all tests, except the clearance study, male mice
were used. The animals were kept in our animal facility with
intermittent 12 h light and 12 h dark, except for 3 h following
the intravenous injection of a photosensitiser, when they were
kept in the dark.
The tumour model used throughout was the M 1 tumour of
DBA/2 mice (3-methylcholanthrene induced rhabdomyosar-
coma) as described (Ritcher et al., 1990b).
Biodistribution oftritiated analogues ofBPD
The tritiated analogues of BPD were injected intravenously
into tumour bearing DBA/2J mice at a dose of 3.5 mg kg-'
body weight. The levels of radioactivity in the tumour and
other tissues were determined at 24 h intervals (starting at 3 h
post injection) after solubilisation of tissue samples with
Protosol (NEN, Boston, Mass.) as described (Richter et al.,
1990b). Counts per minute (CPM) were converted to disinte-
grations per minute (DPM) by means of the appropriate
standard curves, and related to the wet weight of tissue
samples. At least three mice were tested at each time point
with each BPD analogue. Standard deviation between indivi-
dual samples was on average within 18% of the mean. The
following tissues were tested (listed in alphabetical order):
blood, brain, gall bladder, heart, intestine, kidney, liver, lung,
lymph nodes, muscle, skin (ear), spleen, stomach, thymus and
tumour. The level of radioactivity in the tissues was moni-
tored up to 96 h.
Biodistribution of '4C-BPD-MA
Biodistribution of "'C-BPD-MA was tested mainly for the
purpose of verifying the results obtained with tritiated com-
pounds. Moreover, the relatively low specific activity of the
"'C label did not allow us to study the distribution of BPD-
MA in the body, when concentrations fell below a certain
level. Therefore, only two time points were tested, and the
dose injected was higher than the dose of 3H-BPD-MA. Two
groups of three DBA/2J male mice were injected i.v. with
4 mg kg- body weight of "'C-BPD-MA and sacrificed at 3
and 24 h post injection. Sampling and processing of tissues
were done as described for tritiated analogues.
Plasma clearance and eliminationfrom the body
Two groups of five female DBA/2J mice were injected intra-
venously with 3.5 mg kg-' body weight of either tritiated
(BPD-MD) or "'C-labelled (BPD-DA) BPD-analogues. Sam-
ples of blood, urine and faeces were obtained at 15 min, 1 h,
3 h, 5 h, 8 h, 24 h, 48 h, 72 h and 96 h post i.v. injection and
their radioactivity was determined as described (Richter et
al., 1990b). The results were compared with the results
obtained under the same conditions with 3H-BPD-MA (Rich-
ter et al., 1990b).
Plasma distribution ofBPD analogues
In order to determine distribution of BPD monoacids and
diacids between plasma lipoproteins and other proteins
(mainly albumin) a Rudel's spin (Rudel et al., 1974) (modi-
fied by Dr P.H. Pritchard - personal communication) was
carried out using '4C-labelled BPD-MA and -DA. Each ana-
logue at 50fig ml-' was added to 2 ml of human EDTA-plas-
ma (density adjusted to 1.21 with KBr) and spun under 9 ml
of KBr solution in water (1.21 gml-', 0.1 g EDTAl') at
40,000 r.p.m. for 48 h. Under these conditions plasma lipo-
proteins float to the top of the tube and albumin plus other
protein fractions remain in the lower part of the tube
separated from lipoprotein by the KBr solution. Five frac-
tions were collected and 50 j,l samples were taken for count-
ing in Aquasol (NEN) in a Packard Tri-Carb 4550 liquid
scintillation counter. Counts per minute were converted to
disintegrations per minute by means of a standard curve. The
amounts recovered in each fraction were related to the total
amount of drug injected, and to the amount of protein in
each fraction as determined by Lowry's method (Lowry et
al., 1951).
In vivo/in vitro cytotoxicity test
This test was carried out according to the following protocol:
DBA/2J mice bearing the M1 tumour, grown subcutaneous-
ly, were injected i.v. with a photosensitiser at a given dose
and 3 h later were sacrificed. The tumours were removed,
non-necrotic areas were excised and pressed through a fine
sieve to produce a single cell suspension which was plated in
serum-free DME medium in two 96-well plates (at a concen-
tration of 105 viable cells per well), one of which was exposed
to light immediately after plating. Dark controls were run
concurrently with experimental groups and served as control
values. The excision of tumours and preparation of cell
suspensions was carried out under limited illumination and
was strictly timed. The light source used in this set of experi-
ments consisted of a set of 16 100 W tungsten bulbs (General
Electric; spectrum 400- > 1200 nm). The light was filtered
through a 4 cm thick water filter filled with circulating cool
water. The temperature at the plane of exposure did not
exceed 22°C. The incident light density was 6mWcm-2 as
measured by YSI Kettering Model 65 radiometer, and the
dose delivered was 21.6 J cm-2. Following exposure to light,
foetal calf serum (FCS) was added to a final concentration of
5%, and the cells were cultured overnight following which
they were assessed for viability using the MTT assay as
described (Mosmann, 1983). We have found that this assay,
when carried out at 24 h post light irradiation, correlates
with other assays used routinely for determination of tumour
cell survival post treatment, such as 3H-thymidine incorpora-
tion and a clonogenicity assay (Richter et al., 1990a). This
assay measures the activity of mitochondrial dehydrogenases
as an indication of cell viability and metabolic activity, utilis-
ing the tetrazolium salt, MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide; Sigma Chemical Co., St
Louis, MO) as a substrate. The convenience of this assay is
that it could be carried out in 96-well plates, and results can
be determined quantitatively after 1-3 h incubation with a
substrate by reading O.D. at 600 nm in a conventional
ELISA plate reader (Bio-Rad Model 2550 EIA Reader was
used).
All four analogues were tested in this system using a range
of doses between 1.25-10 mg kg-' body weight. Additional
tests were done using 3H-BPD-MA at a dose of 3 and
4.75 mg kg-' body weight.
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tested in the Ml tumour model. For this purpose, the
tumour was grown intradermally. The protocol was as fol-
lows: 5 x I04 Ml cells were injected intradermally into the
shaved and depilated flanks of DBA/2 CR mice. This result-
ed in the development of tumour 4-5 mm in diameter about
10 days later. When the tumours reached this size, animals
were injected intravenously with a photosensitiser at various
doses, and 3 h later exposed to red light (610-750 nm) from
a xenon arc lamp (Oriel, Model 60021, Stratford, CT). The
illumination field was 10 mm in diameter and centred on the
tumour. The lamp contained a 1,000 W bulb (L5179, Hano-
via, Newark, NJ). The light was filtered through a water
filter, a hot mirror (775 FW82-50, Opticon Corporation,
Waterloo, Ontario) reflecting infrared radiation, and a red
filter (#2403, Swift Glass Company, Elmira, NY 14902). The
incident light density was 175 or 200 mW cm-2, as measured
by a Gentec Model TPM radiometer (Gentec Inc, Sainte-
Foy, Quebec). The doses of light delivered were 157 or
180 J cm-2. The temperature of the surface of tumours dur-
ing the light irradiation did not exceed 35°C.
Two types of tests were carried out. In the short term test
the presence or absence of tumours was scored on day 7 post
treatment. In the long term test we determined the tumour
cure. Animals were followed for 30 days for tumour recur-
rence, since with this model, any recurrences occurred before
day 20. Animals which showed tumour recurrence were
evaluated separately from cured animals, and data shown as
average number of days tumour-free was calculated from
only those animals which had recurrence.
Results
Characteristics ofBPD analogues
The structures of BPD are presented in Figure 1. The molec-
ular weights are 718 and 704 for monoacids and diacids,
respectively. The analogues have very similar absorption
spectra (Table I) with a characteristic major porphyrin peak
in the Soret region (400 nm) and several other peaks outside
the Soret band, the most interesting of which, in terms of
applications in PDT, is the peak at 688 nm (in organic
solvents). In aqueous solvents, this peak is shifted to 692 nm.
Extinction coefficients were determined at 688 nm in 50%
methanol-PBS containing 1% Triton X-100 (which prevents
BPD from sticking to the tubes) to be 33,200 M-'cm-',
33,400 M-' cm-', 40,500 M-' cm-' and 31,600 M-' cm-' for
BPD-MA, -MB, -DA and -DB, respectively.
Biodistribution ofBPD analogues
Biodistribution of tritiated BPD-MA has been reported ear-
lier (Richter et al., 1990b). Since tritium labelling was done
by general exchange it was considered less reliable than
internal '4C labelling. Therefore we repeated the biodistribu-
tion studies using 14C-BPD-MA.
Biodistribution of '4C labelled BPD-MA confirmed the
data obtained with the tritiated compound in that, like 3H-
BPD-MA, it accumulated in liver, spleen and kidneys at
higher concentrations than in the tumour. Likewise, the
highest concentration measured was in the gall bladder at 3 h
post injection. The level of '4C-BPD-MA in blood at 3 h post
injection was similar to the level of 3H-BPD-MA. Concentra-
tions in the tissues, as related to the injected dose, were
similar for both labels (Figure 2), as were the tumour/tissue
ratios (data not shown).
Since the data obtained with '4C-BPD-MA validated the
data obtained with 3H-BPD-MA, we undertook to study
biodistribution of 3H-labelled BPD-MB and -DA. Because
early results showed that the diacid analogues were less active
than monoacid derivatives, work with diacids was carried out
mainly on only one of the analogues, BPD-DA. A com-
parison of tissue levels of tritiated BPD-MA and -DA, at 3 h
post injection, is shown in Table II. Overall, BPD-MB and
BPD-DA distributed similarly to BPD-MA in tumour bear-
R = CO2Me
Figure 1 Structure of four analogues of BPD. 1 - BPD-MA; 2 -
BPD-MB; 3 - BPD-DA; 4 - BPD-DB. Structural differences
between the analogues are highlighted.
Table I The absorption spectra ofmonoacid and diacid analogues of
benzoporphyrin derivative in methanol
Absorption peaks (nm)
BPD-MA BPD-MB BPD-DA BPD-DB
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Figure 2 Comparison between the biodistribution of '4C-labelled
(4 mg kg-') and 3H-labelled (3.5mg kg-') BPD-MA in MI
tumour bearing mice. The concentration of BPD-MA in tissues at
3 h post injection of radiolabelled material was determined by
radioactivity (DPM mg-' wet tissue) and related to the concen-
tration in blood (total DPM injected/2 ml- blood) at 0 h (%
dose). Each value represents mean±s.d., as determined in three
mice.
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ing mice. All three analogues accumulated at higher concent-
rations in the liver, spleen and kidneys than in tumour.
Samples of bile, whenever we were able to test them, con-
tained higher levels of radioactivity than samples of liver
taken at the same time. Tumour/tissue ratios for BPD
analogues at 24 h post injection are presented in Figure 3. It
can be seen here, as well as in Table II, that biodistribution
of these analogues is very similar and no significant
differences were found in any tissue for any of the analogues.
In Table II, the concentrations of either BPD-MA or BPD-
DA in a variety of tissues did not vary significantly. Time
points later than 24 h are not shown although these data
were compiled. All analogues showed similar loss of radioac-
tivity in all tissues tested at these later times points.
Plasma clearance and eliminationfrom the body
The clearance data obtained with BPD-MA have been pub-
lished earlier (Richter et al., 1990b) and are cited in this
report only for comparison. Clearance of BPD-MB and -DA
was studied using the 3H and "1C label, respectively. For
purpose of comparison the levels of radioactivity (DPM gl.t '
or mg) in samples of blood, urine, and faeces were related to
the level of radioactivity in blood at Oh. This level was
calculated for each BPD analogue in DPM^l-' blood, by
assuming that the total blood volume of a mouse is 2 ml.
The clearance rates for the three analogues were very
similar. They are cleared from the blood very rapidly during
the first 24 h post injection and for all three the clearance
was biphasic (Figure 4). The first phase of rapid clearance
(half-life less than 20 min) was followed by a slower phase
(half-life less than 8 h).
Radioactivity appeared very quickly in the urine (15 min
sample BPD-MB and -DA) and was the highest in the earli-
est samples obtained for all three analogues (Figure 5). Dur-
Table I1 Tumour tissue ratios in mice bearing M-1 tumours, and the
concentrations of BPD-MA and BPD-DA in tissues (DPM mg-' wet
tissues), expressed as the percentage oftheconcentration in blood at 0 h
(total DPM injected 2 ml blood), designated in the table as '% dose',
at 3 h post i.v. injection
BPD-MA BPD-DA
Tumour/tissue Tumour/tissue
Tissue % Dose ratio % Dose ratio
Blood 3.15 1.09 3.22 0.84
Brain 0.44 7.79 1.33 2.03
Intestine 2.91 1.18 2.02 1.34
Kidney 3.61 0.95 6.19 0.44
Lung 4.28 0.80 4.22 0.64
Liver 19.83 0.17 11.81 0.23
Muscle 0.83 4.13 1.28 2.11
Skin 1.34 2.56 1.29 2.09
Spleen 5.00 0.69 4.20 0.69
Tumour 3.43 - 2.70
4-
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Figure 3 Tumour tissue ratios at 24 h post i.v. injection of
tritiated BPD-analogues at the dose of 3.5 mg kg-' body weight.
The values were obtained in M1 tumour bearing mice.
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Figure 4 Clearance of radiolabelled analogues of BPD (3H-BPD-
MA, 3H-BPD-MB, '4C-BPD-DA) from blood after intravenous
injection at a dose of 3.5 mg kg-' body weight. The radioactivity
in blood (DPM gl-') at various times post injection was related
to the calculated level at radioactivity in blood at 0 h (total DPM
injected/2 ml-' of blood). Each value represents mean± s.d. of
data obtained in five mice.
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Figure 5 Levels of radioactivity in the urine of various tissues
after intravenous injection of radiolabelled analogues of BPD
(3H-BPD-MA, 3H-BPD-MB, "4C-BPD-DA) at a dose of 3.5 mg
kg-' body weight. The radioactivity (DPM g -' urine) was ex-
pressed as the percentage of radioactivity in blood (DPMftl-') at
0 h. Each value represents mean±s.d. of data obtained in five
mice.
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Figure 6 Levels of radioactivity in faeces at various times after
intravenous injection of radiolabelled analogues of BPD (3H-
BPD-MA, 3H-BPD-MB, "'C-BPD-DA) at a dose of 3.5 mg kg-'
body weight. The radioactivity (DPM mg faeces) was expressed
as the percentage of radioactivity in blood (DPMfdl-') at Oh.
Each value represents mean±s.d. of data obtained in five mice.
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ing the first 24 h post injection, 4% of the total dose of
BPD-MA, 6% of BPD-MB and 1.6% of BPD-DA were
excreted in the urine. During the next 96 h less than 1% of
the injected dose of 3H-BPD-MA and -MB cleared daily via
urine. However, the radioactivity of '4C-BPD-DA was some-
what increased toward 24 h post injection (Figure 5) and
remained at the level of 1-2% of the injected dose during the
next few days.
Radioactivity in the faeces peaked between 5-8 h post
injection (Figure 6). All three analogues cleared mainly with
faeces. The majority of the injected dose of 3H-BPD-MA
(60%), 3H-BPD-MB (79%) and '4C-BPD-DA (90%) cleared
with faeces during the first 24h. Thereafter, the levels of
radioactivity in faeces were very low.
Plasma biodistribution ofBPD analogues
There were both some similarities and some differences in
plasma protein distribution between '4C-BPD-MA and `4C-
BPD-DA. Both analogues achieved the highest concentra-
tions in plasma lipoprotein fraction (14.8 ± 1.6 (s.d.) jig 14C-
BPD-MA mg-' protein, 22.0 ± 4.0 (s.d.) yg "4C-BPD-DA
mg' protein). However, while 76 ± 2.7% (s.d.) of "4C-BPD-
DA distributed with lipoprotein fraction, only 49.1 ± 2.6%
s.d. of "4C-BPD-MA associated with this fraction (Figure 7).
Conversely, more "4C-BPD-MA (0.54 ± 0.01 (s.d.) jgmg-'
protein than "C-BPD-DA (0.29 ± 0.03 (s.d.) itg mg-' pro-
tein) was associated with the albumin fraction. In relation to
the total dose of radioactivity 35.9 ± 0.1% (s.d.) of '4C-BPD-
MA as opposed to 19.3 ± 2.3% (s.d.) of "4C-BPD-DA was
bound to albumin (Figure 7).
In vivo/in vitro cytotoxicity test
During these studies, we developed an assay to test how
much photodynamically active photosensitiser (unchanged by
metabolism) was present in cell-bound form in tumour tissue
at any given time. The data reported here support the idea
that this approach may be suitable for relatively rapid eval-
uation of photosensitisers for PDT. Tumours were removed
from mice 3 h following i.v. injection of BPD. Single cell
suspensions from removed tumours were exposed to light
following which the percentage of cells killed was measured.
This test system was thoroughly evaluated in our lab-
oratory before we started using it routinely. Statistical
evaluation (analysis of covariance) of the data obtained with
BPD-MA and Photofrin® (4 mg kg-') at 3 and 24 h post i.v.
injection in the Ml tumour system have shown this test to be
reliable, provided the processing time (time between mincing
the tumour and exposure to light) is strictly controlled. Addi-
tional test using tritiated BPD-MA (at 3 and 4.75 mgkg-';
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Figure 8 Correlation between the concentration of 3H-BPD-MA
in tumour tissue and in tumour cells extracted from the tumour
and used in the in vivo/in vitro assay, following the injection of
the radiolabelled photosensitiser into tumour bearing mice.
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Figure 9 In vivo/in vitro cytotoxicity test using M1 tumour - see
text for details. Each dose of BPD analogues was injected into
tumour bearing mice (groups vary between 4 and 10) and the
results are expressed as the average percentage of tumour cells
killed on exposure to wide spectrum light (21.6Jcm-2) in vitro.
Error bars represent standard error. Dose levels used for BPD-
DB alone were at 5 and 2.5 mg kg-' at which dose no cell killing
was obtained.
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Figure 7 Distributon of '4C-labelled BPD-MA and -DA between
human plasma protein fractions. The amount of radioactivity in
each fraction was expressed as the percentage of the total radio-
activity added to plasma. Each value represents mean± s.d. of
three determinations. Fraction No. I contains most of plasma
lipoproteins, fraction No. 3 contains most of plasma albumin.
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Figure 10 In vivo tumour photosensitising efficiency of BPD-MA
was tested in MI tumour-DBA/2 mouse model. Tumours are
exposed to red light (151 J cm-2) at 3 h post intravenous injection
of various doses of BPD-MA. Absence of tumour on day 7 post
treatment was considered a positive response. The effect of each
dose was determined in 20 mice.92 A.M. RICHTER et al.
Table III Photosensitising activity of BPD analogues in vivo (4 mg
kg-' body weight, light irradiation at 3 h post i.v. injection). Tumour
bearing animals were followed for 30 days following treatment to
determine when or if tumour regrowth occurred
Tumour mass at
time oflight
Number Days tumour Number treatment (mm3)
Photosensitiser ofanimals free (PR)' ofcures*' x+s.d.
Experiment 1(a)***)
None 5 3 0 20.5± 8.7
BPD-MA 8 8 7 27.6± 10.2
BPD-DA 7 0 0 33.1± 17.3
BPD-DA & DB 6 0 0 21.7±6.0
Experiment 2(b)
BPD-DA & DB 6 0 0 25.4± 8.4
Experiment 3(c)
None 5 0 0 31.0± 37.6
BPD-MA 10 12 8 24.4± 7.9
BPD-MB 8 14 3 35.5± 20.3
*Partial response; average number ofdays before tumours recurred.
"Animals whose tumours regressed and who remained tumour-free for
30 days.
` Light dose was (a) 200mw cm-2, 180 J cm-2; (b) 200 mw
cm-2, 360 Jcm-2; (c) 200 mw cm-2, 150 J cm2.
under equivalent light conditions) added confidence to the
test in that the percentage of the extracted tumour cells killed
by light activation correlated with their content of
radiolabelled BPD-MA (correlation coefficient R = 0.85).
Moreover, the concentration of 3H-BPD-MA in the extracted
tumour cells correlated with the concentration in tumour
tissue samples obtained from the same tumour (Figure 8).
This test detects only the presence of the fraction ofphoto-
sensitiser which is directly bound to tumour cells, and not
washed out during the process of dispersing tumour cells.
Studies with radiolabelled BPD-MA have shown that only
27.1 ± 6.5% of drug in tumour is bound to cells. Light
irradiation at 3 h post injection has been chosen based on the
results of preliminary tests indicating that the efficiency of
photosensitisation with BPD-MA decreased with time during
the 24 h post i.v. injection. In this assay, both monoacids
showed good photosensitisation of tumour cells, whereas
both diacids performed poorly (Figure 9).
Tumour photosensitisation in vivo
Encouraging preliminary results induced us to test BPD-MA,
more thoroughly than any other analogue of BPD, for its
tumour photosensitising potency in vivo using the M1 tumour
model in DBA/2 mice. The fast clearance and metabolism of
BPD-MA (Richter et al., 1990b) suggested that irradiation of
tumours at 24 h, might not give optimal results. The time of
light irradiation after i.v. injection was chosen as 3 h since
the results of tests done at 1, 3, 4.5, 6 and 24 h indicated loss
of photosensitising potency with time after the injection (data
not shown).
A dose-response curve for BPD-MA was determined in a
short term assay in which M1 tumours were exposed to light
(175 mW cm-2, 157 J cm-2) at 3 h post i.v. injection of 2, 3, 4
or 5 mg kg-' body weight. Absence of tumours on day 7 post
treatment was considered a positive response, and tumour
regrowth was considered a negative response. In this test the
concentration of BPD-MA resulting in 50% mice free of
tumours was obtained from the curve and was between 2 and
2.5 mg kg-' body weight (Figure 10).
BPD-MA and other analogues were also tested under the
conditions producing some long term cure. In this assay the
dose of BPD-MA was 4 mg kg-' body weight, light exposure
at 3 h post injection. Tumour recurrence was assessed by
daily observation of treated animals for 30 days. Animals
which were tumour free on day 30 were considered cured.
The percentage of cured animals in treated groups is shown
in Table III. Partial response was defined as animals in which
complete tumour ablation was observed following treatment,
but in whom tumours recurred, usually between 4 and 15
days post treatment. The average number of days tumour-
free was determined for each treated group (it did not include
cured animals). It is evident that BPD monoacids are efficient
photosensitisers in this system, while diacids are inefficient. In
cases where tumours responded to treatment, the darkening
of tumours immediately after the exposure to light demon-
strated destruction of tumour vasculature and hemorrhage
indicating that accumulation of photosensitiser molecules in
both tumour cells and tumour vasculature could contribute
to the photodynamic effect. This was followed by tumour
necrosis and formation of an eschar, which included the skin
overlaying the tumour. Within 10-14 days the area healed
and hair regrew.
Discussion
The experimental work reported in this paper showed that
the monoacid, ring A analogue of BPD (BPD-MA) is cap-
able of efficient photosensitisation of tumour cells not only in
vitro as reported earlier (Richter et al., 1990a), but also in
vivo. Its potential for use in photodynamic therapy for cancer
is based on structural characteristics which enable photosen-
sitiser molecules to absorb the photons of visible light and
use the absorbed energy to reach higher energy levels and
eventually to react with a molecular oxygen. This results in
production of singlet oxygen which is considered responsible
for most of the damage leading to tumour cell death and
tumour ablation. One of the most advantageous characteris-
tics of BPD-MA, in this respect, is its ability to efficiently
absorb red light which penetrates tissues deeper than shorter
wavelength light. Its 692 nm absorption peak is also free
from competition for light by haemoglobin, which absorbs
light below 600 nm (Parish, 1983). Another advantageous
characteristic of BPD-MA is its lipophilicity, which enhances
association with the cell membrane. We believe that it is
lipophilicity that makes BPD-MA an efficient photosensitiser
in vitro as well as in vivo. Solubilisation of a photosensitiser
in the lipid bilayer of the cell membrane has been pointed out
as a major factor in photosensitiser's efficiency (Emiliani &
Delmelle, 1983). The in vivo/in vitro test showed that BPD-
MA associates with tumour cells after in vivo injection and
does not wash out in medium during the extraction of cells
for in vitro exposure to light. Fast clearance from body fluids
and tissues is of advantage as well, because persistent pre-
sence of photosensitiser in normal tissues results in adverse
effects such as skin photosensitivity. BPD-MA does not cause
any significant skin photosensitivity past 24 h post injection
(Richter et al., 1988).
Availability of close structural analogues of BPD gave us
the opportunity to study the effects of characteristics which
may contribute to the overall performance of a molecule as a
tumour photosensitiser. It is interesting that all four BPD
analogues have almost identical absorption spectra (Table I)
and very similar extinction coefficients, and in non-biological
systems produce singlet oxygen equally efficiently (R. Bensas-
son, personal communication). Yet in biological systems they
do not photosensitise cells with equal efficiency. We have
attempted to address the question as to what characteristics
contribute to good photosensitisation in biological systems.
All BPD analogues consist of a reduced porphyrin macro-
cycle with a cyclohexadiene ring fused at the ring A or B of
the macrocycle (Figure 1). This cyclohexadiene ring may be
responsible for the high photosensitising potency of BPD
analogues in vitro where they were active in micromolar
concentrations. Structure-activity relationship studies carried
out by Morgan et al. (1987b) indicated that the photosensitis-
ing activity of several compounds derived from a basic por-
phyrin structure was greatest in compounds having a 'bulky
substitution' in the form of a five or six member ring at the
reduced prophyrin residue. It is the basic structure of BPD
analogues which is likely responsible for a similar pattern of
clearance and biodistribution in mice. In fact this pattern
may be common to all porphyrins since a similar pattern (the
bi-phasic clearance from blood, the majority clearing with
faeces and only a small portion with urine), has been report-
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biodistribution and clearance of all BPD analogues, indicate
that differences in photosensitising potency must be attrib-
utable to events occurring at the cellular level.
The position of the cyclohexadiene ring at the porphyrin
ring A or B (Figure 1) affects the solubility of the molecule.
BPD-MB is more lipophilic and even less soluble than BPD-
MA in aqueous solvents, a sonication was required to obtain
concentrations required for injection into animals. However,
the increased lipophilicity did not seem to give BPD-MB any
advantage over BPD-MA. Reduction in photosensitising
potency of phthalocyanines due to low solubility has been
reported (Brasseur et al., 1988).
The substitution of the ester group of monoacids with an
acid group at rings C or D of the porphyrin macrocycle,
resulting in formation of diacid analogues of BPD (Figure 1),
made the molecule less hydrophobic, more negatively
charged and much less effective as a photosensitiser. These
characteristics are most likely responsible for the observed
difference in photosensitising potencies between monoacid
and diacid analogues, both in vitro and in vivo. It is possible
that either reduced hydrophobicity or increased negative
charge, or both, affect the association of diacids with tumour
cells and result in lower activity in vitro as well as failure in
the in vivo/in vitro test and in vivo tumour eradication. The
same characteristics may be responsible for the observed
differences in binding to plasma proteins between BPD-DA
and BPD-MA. Lower hydrophobicity of BPD-DA may be
responsible for its lower binding to albumins than BPD-MA.
Rotenberg et al. (1987) reported a positive correlation
between the hydrophobicity of side chains of the structurally
related porphyrins and affinity to albumin. However, even
for monoacid the binding to albumin is only transient, and
after 24 h incubation in blood is reduced from 35.90% (as
reported here) to 6% (as reported earlier; Allison et al.,
1990). Similar transient binding to albumin has been reported
for hematoporphyrin (Jori et al., 1984). Therefore, although
the difference in albumin binding reflects some functional
differences between monoacid and diacid molecules, it is not
likely to be a major factor in photosensitising efficiency of
the molecules.
Increased presence of BPD-DA in lipoprotein fraction, as
compared to BPD-MA, may result from its stronger negative
charge. As reported earlier (Allison et al., 1990) BPD-DA
associates more (54%) than BPD-MA (37%) with high den-
sity lipoproteins (HDL). HDL contain more apolipoprotein
E (50 mol %; Gotto et al., 1986) than other types of lipo-
proteins. Apolipoprotein E has positively charged sites at the
binding site for low density lipoprotein (LDL) receptor and it
is possible that BPD-DA may be more electrostatically
attracted to these sites.
Nevertheless, differences in binding to plasma protein can-
not account for the difference in in vivo and in vitro
photosensitising potency observed between BPD-MA and
BPD-DA. They indicate, however, the difference in binding
properties between these two analogues, which most likely
play a major role in the photosensitisation. The binding
characteristics of BPD analogues are the subject of ongoing
collaborative studies.
In conclusion, data obtained in vivo with BPD analogues
confirmed the order of photosensitising potencies determined
in vitro. Monoacid forms were at least five times as potent as
diacid forms in photosensitisation of tumour cells in vitro,
and they were also more potent photosensitisers in vivo.
Although photosensitiser activity in vitro often does not cor-
relate with the activity in vivo, in case of BPD analogues in
vitro and in vivo activities were comparable. Their fate in the
body (similar patterns of distribution and clearance) did not
change the order of their photosensitising potencies which is
most likely due to their binding properties at the level of
cellular or subcellular membranes. At this level small struc-
tural differences between these molecules seem to matter. The
characteristics which are considered responsible for the differ-
ence in photosensitising potencies of monoacid and diacid
analogues are lipophilicity and possibly a negative charge.
This work has been supported by Natural Sciences and Engineering
Research Council of Canada Grant No. 5-80268.
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